1. Home
  2. KMDA vs VNDA Comparison

KMDA vs VNDA Comparison

Compare KMDA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$8.42

Market Cap

488.6M

Sector

Health Care

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$7.31

Market Cap

474.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMDA
VNDA
Founded
1990
2002
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
488.6M
474.0M
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
KMDA
VNDA
Price
$8.42
$7.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$14.00
$14.90
AVG Volume (30 Days)
61.1K
1.5M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
2.96%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$216,105,000.00
Revenue This Year
$13.94
$21.35
Revenue Next Year
$9.84
$37.40
P/E Ratio
$24.59
N/A
Revenue Growth
N/A
8.72
52 Week Low
$6.29
$3.81
52 Week High
$9.35
$9.91

Technical Indicators

Market Signals
Indicator
KMDA
VNDA
Relative Strength Index (RSI) 48.73 47.26
Support Level $8.38 $7.12
Resistance Level $8.88 $8.29
Average True Range (ATR) 0.19 0.33
MACD 0.02 0.02
Stochastic Oscillator 72.22 58.20

Price Performance

Historical Comparison
KMDA
VNDA

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: